Discrepancies in regional lung cancer multidisciplinary team decisions can be reduced through national consensus meetings
DOI:
https://doi.org/10.2340/1651-226X.2025.43314Keywords:
lung cancer, Scandinavian and Nordic countries, multidisciplinary team conference, tumor board, consensusAbstract
Background: Multidisciplinary team (MDT) meetings are a gold standard in lung cancer care. A recent study identified discrepancies in staging and treatment recommendations among Danish lung cancer MDTs based on fictitious cases. This short report presents the results from a national lung cancer MDT meeting, which reevaluated these difficult cases.
Method: Fifteen difficult cases were reevaluated by 52 lung cancer specialists from across Denmark, representing oncology, pulmonology, radiology, nuclear medicine, and thoracic surgery. Participants were grouped together with their usual MDT colleagues. Cases were presented in a plenary session, and participants discussed cases staging, treatment intent, and treatment options as they would in a regular MDT with their colleagues. If disagreement between the individual MDT groups occurred, the case was further discussed in plenum. Descriptive statistics were used to assess agreement.
Results: Complete agreement on tumor node metastasis (TNM) staging, treatment intent, and recommended treatment was reached in three cases (20%). Agreement on stage was reached in 10 cases (67%). Discrepancies regarding stage arose from debates regarding multifocal versus synchronous lung cancers, degree of lymph node involvement and the malignancy status of pleural fluid. Differences in treatment recommendations were mainly due to insufficient information about performance status.
Interpretation: Staging and treatment intent discrepancies among Danish lung cancer MDTs were considerably reduced when complex cases were discussed in a national plenary session. However, for difficult lung cancer cases, MDTs recommend different treatment, highlighting the need for a national MDT meeting for a select group of lung cancer patients.
Downloads
References
Stirling RG, Harrison A, Huang J, Lee V, Taverner J, Barnes H. Multidisciplinary meeting review in non-small cell lung cancer: a systematic review and meta-analysis. Eur Respir Rev. 2024;33(172):230157.
https://doi.org/10.1183/16000617.0157-2023 DOI: https://doi.org/10.1183/16000617.0157-2023
Forrest LM, McMillan DC, McArdle CS, Dunlop DJ. An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2005;93(9):977–8.
https://doi.org/10.1038/sj.bjc.6602825 DOI: https://doi.org/10.1038/sj.bjc.6602825
Heinke MY, Vinod SK. The impact of lung cancer multidisciplinary care on patient outcomes. Transl Lung Cancer Res. 2020;9(4):1639–53.
https://doi.org/10.21037/tlcr.2019.11.03 DOI: https://doi.org/10.21037/tlcr.2019.11.03
Stone E, Rankin N, Kerr S, Fong K, Currow DC, Phillips J, et al. Does presentation at multidisciplinary team meetings improve lung cancer survival? Findings from a consecutive cohort study. Lung Cancer. 2018;124:199–204.
https://doi.org/10.1016/j.lungcan.2018.07.032 DOI: https://doi.org/10.1016/j.lungcan.2018.07.032
Tanner NT, Gomez M, Rainwater C, Nietert PJ, Simon GR, Green MR, et al. Physician preferences for management of patients with stage IIIA NSCLC impact of bulk of nodal disease on therapy selection. J Thorac Oncol. 2012;7(2):365–9.
https://doi.org/10.1097/jto.0b013e31823a385f DOI: https://doi.org/10.1097/JTO.0b013e31823a385f
Hoeijmakers F, Heineman DJ, Daniels JM, Beck N, Tollenaar RAEM, Wouters MWJM, et al. Variation between multidisciplinary tumor boards in clinical staging and treatment recommendations for patients with locally advanced non-small cell lung cancer. Chest. 2020;158(6):2675–87.
https://doi.org/10.1016/j.chest.2020.07.054 DOI: https://doi.org/10.1016/j.chest.2020.07.054
Rasmussen TR, Gouliaev A, Jakobsen E, Hjorthaug K, Larsen LU, Meldgaard P, et al. Impact of multidisciplinary team discrepancies on comparative lung cancer outcome analyses and treatment equality. BMC Cancer. 2024;24(1):1423.
https://doi.org/10.1186/s12885-024-13188-4 DOI: https://doi.org/10.1186/s12885-024-13188-4
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–85.
https://doi.org/10.1056/NEJMoa2202170 DOI: https://doi.org/10.1056/NEJMoa2202170
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Anja Gouliaev, Weronika Maria Szejniuk, Joan Fledelius, Hans Henrik Torp Madsen, Rene Horsleben Petersen, Torben Riis Rasmussen
This work is licensed under a Creative Commons Attribution 4.0 International License.
